A science-backed overview of the compounds most studied for metabolic and fat loss applications — mechanism of action, receptor pharmacology, and published research findings.
Peptide-based compounds have become the most active area of metabolic research in the last decade — driven by the discovery that incretin hormones and their synthetic analogs produce profound effects on energy homeostasis, adipose tissue regulation, and body composition in both preclinical and clinical models.
The incretin system — centered on GLP-1 and GIP — regulates insulin secretion, gastric emptying, appetite signaling, and energy partitioning through receptor-mediated pathways in the gut, pancreas, brain, and adipose tissue. Alongside this, the GH/IGF-1 axis offers a distinct mechanism for visceral fat mobilization, and anti-inflammatory pathways represent a third mechanistic angle increasingly studied in metabolic dysfunction contexts.
This guide covers five compounds representing these three distinct research approaches: incretin receptor agonism (GLP-3 RT, GLP-2 TRZ), GH axis stimulation (Tesamorelin), anti-inflammatory metabolic pathways (KLOW), and gut-metabolic axis regulation (BPC-157).
COA-verified, same-day shipping from Wisconsin. All five compounds in this guide are available from Evo Peptides, lyophilized and third-party tested. Orders placed before 3:00 PM CST ship same day to all 50 states.
GLP-3 RT is the most pharmacologically ambitious compound in this class — a triple receptor agonist simultaneously activating GLP-1, GIP, and glucagon receptors. The glucagon receptor (GcgR) component is the key distinction: it drives additive thermogenesis and hepatic lipolysis through pathways that dual agonists cannot access.
Phase II data published in NEJM (2023) documented dose-dependent changes in body weight and cardiometabolic markers over 24 weeks. Phase III programs are ongoing as of 2026, making GLP-3 RT the most forward-looking compound in incretin metabolic research.
GLP-2 TRZ is the most clinically characterized compound in this guide. As a deliberate GIP-biased dual agonist, it carries the deepest published evidence base — the full SURPASS and SURMOUNT Phase III programs covering glycemic endpoints, adiposity, cardiovascular markers, and 72-week metabolic outcomes.
Mechanistic studies with receptor-specific antibody blockade have characterized the distinct GIPR vs GLP-1R contributions to adipose tissue outcomes, making GLP-2 TRZ a rigorous reference compound for incretin pathway research.
Tesamorelin operates through an entirely different axis than the incretin compounds above — not through gut hormones or appetite signaling, but by stimulating pituitary GHRH receptors to produce pulsatile growth hormone release. GH then drives lipolysis in adipose tissue, particularly visceral fat depots, via hormone-sensitive lipase activation and IGF-1 elevation.
This GH-mediated lipolysis mechanism is distinct and complementary to GLP-1/GIP receptor agonism, targeting visceral fat through a downstream hormonal cascade rather than central appetite regulation. Its FDA approval as Egrifta (2010) for HIV-associated lipodystrophy provides a rare clinical-grade evidence base in the peptide research space.
Key published findings include significant trunk fat area reduction versus placebo at 26 weeks in lipodystrophy trials, consistent dose-dependent IGF-1 elevation across multiple study populations, augmented GH mean pulse amplitude while preserving pulsatile release pattern, and notable cognitive function findings in a 20-week mild cognitive impairment trial.
KLOW represents a mechanistically distinct research approach — targeting the inflammatory pathways underlying insulin resistance and metabolic dysfunction rather than energy intake or GH axis signaling. Chronic low-grade inflammation is a well-characterized contributor to adipogenesis dysregulation and impaired metabolic signaling.
The two-component architecture targets this through non-overlapping pathways: KPV suppresses NF-κB-driven cytokine production via melanocortin receptors, while Low-Dose Naltrexone modulates innate immune signaling through TLR4 antagonism and endogenous opioid upregulation.
BPC-157's relevance to fat loss research is indirect but mechanistically grounded. Its primary metabolic research interest lies in gut-brain axis modulation, NO synthase pathway activation, and documented influence on dopaminergic and serotonergic signaling — all of which intersect with appetite regulation, gut microenvironment integrity, and systemic metabolic homeostasis.
| Compound | Primary Mechanism | GcgR | GH Axis | Anti-Inflam. | Research Depth |
|---|---|---|---|---|---|
| GLP-3 RT | GLP-1R · GIPR · GcgR | ✓ | — | — | Emerging (Ph III) |
| GLP-2 TRZ | GLP-1R · GIPR | — | — | — | Established (Ph III) |
| Tesamorelin | GHRHR → pulsatile GH | — | ✓ | — | Established (FDA) |
| KLOW 80mg | NF-κB · TLR4 suppression | — | — | ✓ | Preclinical + clinical |
| BPC-157 | NO pathway · Gut-brain axis | — | — | ✓ | Preclinical (extensive) |
Research design note: These five compounds operate through non-overlapping mechanisms. GLP-3 RT and GLP-2 TRZ address incretin receptor pharmacology; Tesamorelin addresses GH-axis lipolysis; KLOW addresses inflammatory metabolic pathways; BPC-157 addresses gut-metabolic axis integrity. They are complementary research targets, not substitutes.
The choice of compound depends entirely on which mechanism the research program is designed to investigate. Incretin receptor agonism studies should center on GLP-2 TRZ (for established dual-axis pharmacology) or GLP-3 RT (for triple-mechanism investigation including GcgR contribution). GH-axis lipolysis research should use Tesamorelin, which provides the deepest published clinical dataset for GHRH-mediated visceral fat reduction. Anti-inflammatory metabolic pathway research is better served by KLOW.
Tesamorelin's GH-axis mechanism makes it uniquely relevant to research examining visceral fat as a specific depot — not total adiposity. The GH/IGF-1 pathway preferentially mobilizes visceral fat over subcutaneous, a distinction that is mechanistically important for research programs examining abdominal adiposity, cardiovascular risk markers, or lipodystrophy models. Its FDA approval status also provides a level of translational credibility rare among research peptides.
All five compounds are available from Evo Peptides, operating out of Wisconsin with same-day shipping on orders before 3:00 PM CST. Each compound is lyophilized for stability, COA-verified by independent laboratory testing, and ships to all 50 states. Batch-specific COA documents are available at evopeptidesus.com/coas.